{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-036131","form_type":"8-K","ticker":"CBUS","cik":"0001705843","company_name":"Cibus, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.183428+00:00","generated_at":"2026-05-31T11:03:29.933923+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cibus reports Q2 net loss of $28.5M; cash $30M; sees runway into Q4 2024","bullets":["Net loss of $28.5M ($1.14 loss per share) vs $20.5M loss in year-ago period (not comparable due to merger).","Cash and cash equivalents $30M; expects to fund operations into Q4 2024 without additional financing.","R&D expense $13.0M (+55% YoY); SG&A $9.3M (-16% YoY).","Commercial progress: signed fourth rice HT trait customer FEDEARROZ; Wheat platform operational; Sclerotinia and NUE edits achieved in canola.","Regulatory advances in Canada, UK, EU; IP expanded across 10 trait families."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-036131","json":"https://secwatch.observer/filing/0001628280-24-036131.json","markdown":"https://secwatch.observer/filing/0001628280-24-036131.md","text":"https://secwatch.observer/filing/0001628280-24-036131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1705843/000162828024036131/0001628280-24-036131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1705843/000162828024036131/cbus-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:03:29.933923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}